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Numerous studies have shown the pathological inﬂuence anti-phospholipid antibodies (APLA) have on
the physiology of the single neuron as well as the function of the entire human nervous system.
The inﬂuence is well demonstrated in the antiphospholipid syndrome (APS). This syndrome is
characterized by a triad of arterial or venous thrombotic events, recurrent fetal loss and
thrombocytopenic purpura. The syndrome exhibits different neurological pathologies such as: chorea,
seizures, transverse myelopathy, migraine, cerebral ataxia, hemiballismus and transient global amnesia,
which are not fully explained by the procoagulopathic trait of APLA. A study on mice induced with
APS demonstrated hyperactive behavior when compared to the control group. The information
gathered from these different studies raised the question whether APLA has any part in the etiology of
Attention Deﬁcit/Hyperactive Disorder (ADHD) in children.
We compared 41 children diagnosed with ADHD to a control of 28 healthy children. Blood drawn
from the two groups was screened using ELISA for the presence of anti-cardiolipin antibodies, anti-
b2GP antibodies, anti-phosphatidyleserine antibodies and anti-ethanolamine antibodies. The results
show no signiﬁcant difference in the level of antiphospholipid antibodies (APLA) measured between
the children diagnosed with ADHD and the control group.
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INTRODUCTION
Attention Deﬁcit/Hyperactivity Disorder (ADHD) is one
of the most prevalent disorders in childhood and
adolescence, with different epidemiological studies
showing a prevalence of 3–5% in all school aged children
in the United States (Robinson et al., 1999). Almost half
of all visits to neurologists, neuropsychologists and
psychiatrists in this age group are ADHD related
(Cantwell, 1996). Patients with ADHD display increased
motor activity, inattention and impulsivity. On the long
term, a large percent of these children develop
psychological and developmental sequels such as:
learning disability, stress disorder, mood disorder,
communication and language difﬁculties, dyspraxia and
Tourette’s disorder. Although ADHD remains a hetero-
geneous condition for which no one etiology has emerged,
there has been growing evidence for the explanation that
the condition is caused by a complex interaction of
biological and environmental factors. The treatments
are numerous, none being deﬁnitive. The most effective is
a combination of behavioral and pharmacological
treatments (Elia et al., 1999).
Antiphospholipid antibodies (APLA) are a diverse
group of antibodies directed against proteins that are
bound to phospholipids inside the cell’s wall. Out of the
proteins, the most investigated is b2GP and out of the
phospholipids, the most investigated are: cardiolipin,
phosphatidylserine, ethanolamine and phosphatidyl-
choline. The inﬂuence, these antibodies have on human
health is well documented in the antiphospholipid
syndrome (APS). This syndrome as ﬁrst described
by Hughes (1983), is characterized by the appearance
of venous or arterial thrombosis, repeated abor-
tions, thrombocytopenia and the existence of APLA
(particularly, lupus anticoagulant and anti-cardiolipin).
A wide spectrum of other clinical manifestations have
been reported recently in association with APS, including
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complications and diverse neurological disorders invol-
ving mainly the central nervous system (CNS) (Brey et al.,
1996). The neurological manifestations presented by most
patients with APS are antibody-induced coagulopathies.
However, neurological manifestations other than stroke
are seen in these patients, such as: chorea, seizures,
transverse myelopathy, migraine, cerebral ataxia, hemi-
ballismus and transient global amnesia, which are not
fully explained by the procoagulopathic trait of APLA
(Brey et al., 1996).
Recent in-vitro studies have shown the pathological
inﬂuence APLA have on neural tissue. Different research
groups have demonstrated that APLA can bind to
astrocytes and neurons as well as ependima and myelin
cells (Kent et al., 1997, 2000; Caronti et al., 1998;
Chapmanetal.,1999). Theinﬂuencethese have onnormal
neuron physiology was demonstrated by Chapman et al.
(1999). APLA taken from patients with increased levels of
APLA depolarized brain cells in-vitro. The in-vivo effect
of APLA was demonstrated by Ziporen et al. (1997). This
group induced APS on mice using monoclonal anti-
cardiolipin antibodies. In addition to fetus resorptions and
thrombocytopenia, these mice were impaired neurologi-
cally and exhibited hyperactive behavior when compared
to normal control. The sum of all this gathered information
raised the question whether there is an etiological
connection between APLA and hyperactivity as seen in
children with ADHD.
PATIENTS AND METHODS
Patients
In this work we compared serum samples of 41
ADHD diagnosed children to that of 28 healthy children.
The work received the approval of the ethics committees
of Sheba medical center, Tel-Hashmer, Israel and
Sourasky medical center, Tel-Aviv, Israel. Informed
consent was obtained from all parents of the subjects
studied.
Children with ADHD
The patients were enrolled into the study from the patient
population of the child development unit in Sheba medical
center, and the pediatric neurology unit in Sourasky
medical center. Each patient’s ﬁle was screened to verify
the diagnosis of ADHD according to the DSM IV
guidelines (American Psychiatric Association, 1994). The
picked age rangewas 4–15. The children and their parents
were both invited and on arrival, they ﬁlled in a structured
questionnaire which recorded the demographic data,
pharmacological treatment, coagulopathies if presented
in the patient or his close family, family history of
autoimmune diseases and family history of ADHD or
hyperactivity.
Healthy Children
The blood samples were drawn from healthy children
undergoing elective surgery (mainly inguinal hernias and
undescended testis). The picked age range was similar to
previously mentioned group and in this group, the same
structured questionnaire was ﬁlled by the parents. These
children had no major illness or knowledge of a recent
infectious disease. The blood was drawn following full
sedation of the child prior to commencing the surgery.
The child’s parent signed a consent form and ﬁlled in the
same questionnaires that the previous group was
presented.
Methods
Approximately, 5ml of blood was drawn from each subject
for the following laboratory analysis; quantitative levels of
immunoglobulins (class G and M) of anti-cardiolipin (aCL)
antibodies, beta-2-glycoprotein I (b2GPI) antibodies, anti-
phosphatidylserine antibodies and anti-ethanolamine anti-
bodies. IgG and IgM class antibodies to anti-cardiolipin
antibodies and b2GPI antibodies were measured by a
commercial enzyme immunoassay (Orgentec Diagnostika
Gmdh, Mainz, Germany) according to the manufacturer’s
instructions. For aCL, a value above 10GPL for IgG and a
value above 7MPL for IgM were considered as “positive”.
For b2GPI, values greater then 8units/ml are considered as
“positive” and values 5–8 are considered “low positive” for
IgG and IgM. Anti-ethanolamine antibodies and anti-
phosphatidylserine antibodies were detected using ELISA.
Microtitre plates (Costar Medium Binding EIA/RIA plates;
Costar, Cambridge, MA, USA) were coated with
100ml/well of phosphatidylserine and ethanolamine. After
incubation with 120ml/well of 10% fetal bovine serum
(Sigma) in TBS for 2h at room temperature the plates were
washedthreetimeswithTBS.Then100ml/wellofstandards
and serum samples diluted 1:100 in TBS were added in
duplicate and the plates were incubated in the refrigerator
(48c) for the night. The plates werewashed three times with
TBS, and 100ml/well of alkaline phosphatase-conjugated
goat anti-human IgG or IgM (ACSC, Wesstbury, NY, USA)
diluted 1:1000 TBS was added. After 2h of incubation
at room temperature, the plates were washed three times
with TBS and 100ml/well of p-nitrophenyl phosphate
(Sigma) dissolved at 1mg/ml in 1M diethanolamine buffer
(pH 9.8) was added. After 15min the wells optic density
were read by an optic reader at 450nm wave length.
Statistical Analysis
All the information gathered from the questionnaires was
entered into an electronic database. All the statistical
analyses were preformed using the BMDP computer
program. ANOVA test was used to compare between
the continuous variables in the two groups. The non-
continuous variables were analyzed using Fisher’s exact
test and Pearson’s Chi-Square where appropriate.
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The study included 70 children. Table I demonstrates the
demographic characteristics of each group. In the ADHD
group the age range is 5–15. The control group has an age
rangeof4–13.ThereisnostatisticaldifferenceðP ¼ 0:001Þ
in the mean age of the two study groups. Forty eight
percent of ADHD parents testiﬁed to a hyperactivity trait
in a ﬁrst degree relative of the tested case. Only 3.5% of
the control parents testiﬁed to a similar trait. The two
groups have similar percentages of positive answers in the
other questions raised in the questionnaire: hypercoagul-
ability in the close family, an autoimmune disease in the
close family and a known coagulation abnormality in the
tested case.
aCL Levels
The mean level of these antibodies in the two groups is
of no signiﬁcant statistical difference as demonstrated in
Fig. 1. A “positive” level (above 10GPL units/ml for IgG
and above 7MPL units/ml for IgM) of these antibodies
was measured for IgG in 12.2 and IgM in 26.8% of the
A D H Dc h i l d r e ni nc o m p a r i s o nt o2 0a n d2 5 % ,
respectively in the control group.
Anti-B2GP Levels
The mean level of these antibodies in the two groups is
of no signiﬁcant statistical difference as demonstrated
in Fig. 2. A “positive” level (above 8units/ml for IgG and
IgM) of these antibodies was measured for IgG in 4.8
and IgM in 2.4% of the ADHD children in comparison to
0 and 5%, respectively, in the control group.
Anti-ethanolamine Levels
The mean level of these antibodies in the two groups is
of no signiﬁcant statistical difference as demonstrated in
Fig. 3. A level of antibodies which is two standard
deviations from the mean was found in 2.4% (1/41) of
the ADHD children for the immunoglobulin G and M
classes. As for the control group a level of two standard
deviations from the mean was found in 3.6% (1/28)
of blood samples for the immunoglobulin G class and
in 10.7% (3/28) of the samples for the immunoglobulin
M class.
Anti-phosphatidylserine Levels
The mean level of these antibodies in the two groups is
of no signiﬁcant statistical difference as demonstrated in
Fig.4. A level of antibodies which is two standard
deviations from the mean was found in 2.4% (1/41) of the
ADHD children for the immunoglobulin G and M classes.
As for the control group a level of two standard deviations
from the mean was not found in any blood sample for
the immunoglobulin G class and in 10.7% (3/28) of
TABLE I Main characteristics of the study population
ADHD group Control group
Number of participants 41 29
Males 90.2% ðN ¼ 37Þ 75.9% ðN ¼ 22Þ
Females 9.8% ðN ¼ 4Þ 24.1% ðN ¼ 7Þ
Mean age 9.98 7.76
Methylphenidate
(Ritalin) takers
23 0
Cloniride takers 3 0
FIGURE 1 Comparison of IgG and IgM anti-cardiolipin antibody
values in ADHD children and in a healthy control. The horizontal lines
indicate means of pooled data for each group.
FIGURE 2 Comparison of IgG and IgM anti-b2GP antibody values in
ADHD children and in a healthy control. The horizontal lines indicate
means of pooled data for each group.
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group had no other “positive” antibodies and their parents
did not report of any family history of coagulopathies,
autoimmune disease or hyperactivity.
DISCUSSION
This study tried to prove a postulated association between
the presence of APLA in children’s blood and the
diagnosis of ADHD in those children. The assumption that
such a connection exists relied on the appearance of
neurological manifestations mainly in APS which are not
fully explained by the procoagulopathic effect these
antibodies induce, the in vivo effect and in vitro effect
these antibodies have on nerve tissue and the hyperactivity
induced on mice when these antibodies were injected to
them. Our study results do not demonstrate an increased
incidence of anticardiolipin antibodies, b2GP antibodies,
anti-phosphatidylserine antibodies and anti-ethanolamine
antibodies in ADHD children when compared to a similar
group of healthy children. The percentage of children
“positive” to the presence of anticardiolipin antibodies
and b2GP antibodies in our study did not differ from
that found in a healthy age matched population as
studied by Avcin et al. (2001). The prevalence of the
other two antibodies (anti-ethanolamine and anti-phos-
phatidylserine) in a healthy population was not studied
from a review of the recent literature.
A connection between APLA and neurological
manifestations in children was demonstrated in a number
of studies. Eriksson et al. (2001), in a study, similar to
ours, found high prevalence of APLA in children with
epilepsy (44% of the studied population). They also
observed a signiﬁcant variation in the prevalence of
aCL in different epileptic syndromes. Yoshimura et al.
(2001) found high prevalence of APLA in children with
benign infantile convulsions when compared to an aged
matched control (88% compared to 17%). A follow up on
these children for two years disproved a number of prior
assumptions: the ﬁrst, in one-third of the children, high
levels of aCL were detected even though they had not
received any anti-epileptic medication and the antibody
level decreased as expected with age without relation to
the dose of drugs or term of therapy; the second, the
frequency of convulsions did not inﬂuence the level of
aCL; the third, the cross-reaction between aCL and
neurons was more likely than the thrombogenic activity
involved in APS as MRI ﬁndings were normal. Since
migraine seems to be more common in patients with SLE,
some studies have investigated a possible association with
aCL (Markus and Hopkinson, 1992), and studies in adults
with migraines have suggested a signiﬁcant relationship
between aCL and migraines (Shuaib et al., 1989; Tietjen
et al., 1998). Verrotti et al. (2001) studied this relationship
in children and adolescents and found no association.
The look for a single cause in syndromes is in times a
very complicated task and in others a futile one. It is
especially true in ADHD, where the diagnosis is not
always made by an objective person and the disorder
withholds a number of subclasses. From the information
gathered to this date, it is believed that ADHD is a
condition caused by a complex interaction of biological
and environmental factors. Hyperactivity is known to
aggregate within families for 25 years and was proved
once more in our study. Twin, family and adoption studies,
have consistently shown that hyperactivity is one of the
most commonly inherited behavioral traits in childhood.
The exact genetic defect or defects are not known. Current
genetic research based on neurophysiological ﬁndings is
centered on genes involved in the dopaminergic and
noradrenergic function. Animal as well as human
FIGURE 3 Comparison of IgG and IgM anti-ethanolamine OD values
in ADHD children and in a healthy control. The horizontal lines indicate
means of pooled data for each group.
FIGURE 4 Comparison of IgG and IgM anti-phosphatidylderine OD
values in ADHD children and in a healthy control. The horizontal lines
indicate means of pooled data for each group.
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ters have in the development of hyperactivity
(Todd and Botteron, 2001). The review by Biederman
and Spencer (2000) emphasizes that an induced change in
these neurotransmitter systems in children with ADHD
affects their behavior and can improve their symptoms.
A recent study by Segman et al. (2002) demonstrates
a possible connection between the immune and these
two neurotransmitters. They studied 86 families
with children diagnosed with ADHD and found a
signiﬁcant association between a variation in the gene
for the immune system protein interleukin-1 (IL-1) and
ADHD. IL-1 has a pivot role in our immune system but
also in the release of dopamine and noradrenalin in
different brain areas.
While genetic studies showed a genetic contribution to
this disorder, they also demonstrated that the environment
played a role as well. The twin study by Goodman
and Stevenson (1989) has concluded that heritability
accounted for 30–40% of the cases, environmental
factors accounted for 10–30% of the cases and 40–50%
was accounted for by speciﬁc environmental effects and
measurement error. The factors that have been shown to
encourage the appearance of ADHD are those environ-
mental factors that affect the ability of the organism to
function or develop at a normal level. Initial studies
centered on dietary substances that can inﬂuence the
appearance of hyperactivity. However, in recent years
additional environmental factors have been found across
many areas including: toxins, allergies to dietary
substances and seasons of birth. Those ADHD studies
that could control best for possible confounding effects
from the environment got better results.
In sum, our study has shown no increased incidence
of APLA in children with ADHD compared with
control subjects. The assumption that such a relation-
ship exists relied on laboratory, animal and human
studies that have demonstrated the inﬂuence these
antibodies have on the single neuron, the entire nervous
system and human behavior. The hypothesis that APLA
can play a role in the etiopathogenesis of ADHD in
children should be tested in larger studies if the
association is to be proved.
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